MassBiologics and the Wadsworth Center teamed up to generate a panel of RBD-specific antibodies (“nanobodies” or VHHs) that can be used for identity tests in the manufacture of SARS-CoV-2 subunit vaccines.
MassBiologics used yeast-display technologies to identify nanobodies specific for each RBD VoC, while Wadsworth Center evaluated the nanobodies’ suitability to function in mock identity tests with drug substances and drug products.
MassBiologics and the Wadsworth Center developed critical reagents for use in developing analytical CMC assays involved in the manufacturing of SARS-CoV-2 subunit vaccines, which can help accelerate the manufacturing process.
The project will develop critical reagents for use in the manufacturing of COVID-19 vaccines.
This project demonstrated a panel of VoC-specific nanobody reagents that improves identity testing for drug companies, resulting in quality benefits across COVID-19 vaccine manufacturing.
GLP-grade quality SARS-CoV-2 RBD protein antigens from wild type, Beta, Delta, and Omicron variants were produced and purified at milligram quantities.
A panel of VoC-specific VHH-IgG antibodies against SARS-CoV-2 RBD spike protein were identified and characterized for binding affinity (ELISA, BLI), SARS-CoV-2 neutralization, and epitope class.
Developed SOPs for RBD and RBD adsorbed binding assays
Mantis, N., Presenter, Spike Identification (SpiID) Nanobody Panel for SARS-CoV-2 VaccineManufacturing, 2023 NIIMBL National Meeting, Washington DC, June 27-29 2023
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
New York State Department of Health (Wadsworth Center)
University of Massachusetts System
